Title |
Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
|
---|---|
Published in |
Retrovirology, February 2013
|
DOI | 10.1186/1742-4690-10-22 |
Pubmed ID | |
Authors |
Thibault Mesplède, Peter K Quashie, Nathan Osman, Yingshan Han, Diane N Singhroy, Yolanda Lie, Christos J Petropoulos, Wei Huang, Mark A Wainberg |
Abstract |
Clinical studies have shown that integrase strand transfer inhibitors can be used to treat HIV-1 infection. Although the first-generation integrase inhibitors are susceptible to the emergence of resistance mutations that impair their efficacy in therapy, such resistance has not been identified to date in drug-naïve patients who have been treated with the second-generation inhibitor dolutegravir. During previous in vitro selection study, we identified a R263K mutation as the most common substitution to arise in the presence of dolutegravir with H51Y arising as a secondary mutation. Additional experiments reported here provide a plausible explanation for the absence of reported dolutegravir resistance among integrase inhibitor-naïve patients to date. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | 33% |
Canada | 1 | 33% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 33% |
Science communicators (journalists, bloggers, editors) | 1 | 33% |
Members of the public | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 1% |
Brazil | 1 | 1% |
Unknown | 79 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 15 | 19% |
Student > Ph. D. Student | 14 | 17% |
Researcher | 11 | 14% |
Other | 10 | 12% |
Student > Bachelor | 6 | 7% |
Other | 14 | 17% |
Unknown | 11 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 25 | 31% |
Agricultural and Biological Sciences | 15 | 19% |
Biochemistry, Genetics and Molecular Biology | 11 | 14% |
Immunology and Microbiology | 7 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 6% |
Other | 4 | 5% |
Unknown | 14 | 17% |